ArticlePloS one2026
An integrated multi-omics study of key mediators and therapeutic targets for doxorubicin-induced atrial fibrillation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxorubicin (DOX), a widely used chemotherapeutic agent for cancer patients, is associated with a significant risk of inducing atrial fibrillation (AF), a serious cardiac complication that impairs patient prognosis. However, the specific molecular and cellular mechanisms linking DOX cardiotoxicity to AF pathogenesis remain poorly understood.
methodsFollowing processing pharmacovigilance analysis of DOX-related AF events, we employed an integrative multi-omics strategy. Differentially expressed genes (DEGs) were first identified from the atrial transcriptomic dataset. Network toxicology was used to predict DOX targets, which were intersected with AF-related genes and DEGs to identify candidate targets. Functional analyses and protein-protein interaction network analysis was applied to pinpoint hub genes. Their predictive performance was validated in independent datasets. Gene set enrichment analysis (GSEA) and immune infiltration profiling (CIBERSORT) were conducted to elucidate biological functions and immune context. Molecular docking simulations validated direct interactions between DOX and selected proteins. Finally, single-cell RNA sequencing (scRNA-seq) analysis resolved the cell-type-specific expression patterns of key targets.
resultsFunctional analyses implicated the candidate genes in critical pathways. 5 hub genes were further selected from candidate genes using the MCC algorithm. Among 5 hub genes, we identified and validated the combination of CCR2, PDE5A, and CXCR2 showed high predictive accuracy for AF (mean AUC = 0.87), with identifying and validating CCR2 and PDE5A significantly and differentially expressed. GSEA linked CCR2 and PDE5A showed different pathways. Immune infiltration analysis revealed significant alterations in macrophages, monocytes, and T cell subsets in AF tissues. Molecular docking confirmed stable, high-affinity binding between DOX and both CCR2 and PDE5A (binding energy < -7 kcal/mol). Crucially, scRNA-seq analysis demonstrated that CCR2 and PDE5A were differentially expressed in atrial macrophages and fibroblasts respectively.
conclusionThis study suggests that CCR2 and PDE5A may serve as central mediators and potential therapeutic targets for DOX-induced AF, though these findings require experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.